Carolyn, it comes back to the three As I mentioned: availability, affordability, and accountability. I think it's very important that Health Canada develop processes, such as products like yttrium and lutetium, or that other medications be approved based on European clinical trials, for example. There's no need to reinvent the wheel.
On June 3rd, 2010. See this statement in context.